Canada: February 2017 Deal Round-Up

The following is a selection of major deals in the life science space that closed or were announced as closed in February 2017.


Date: February 13, 2017

Type: Acquisition

Target: Apteryx, Inc. ("Apteryx")

Acquirer: LED Medical Diagnostics Inc. ("LED") (TSX.V: LMD)

Agent(s): Bloom Burton Securities Inc.

Deal size: Aggregate consideration of US $10.25 million

Description: On February 13, 2017, LED announced that it had completed its acquisition of 100% of the capital stock of Apteryx for aggregate consideration of US $10.25 million. LED paid US $6.987 million in cash and issued approximately 33.9 million common shares of LED at CDN$0.07 per share towards satisfaction of the purchase price, with an additional US $1.2 million to be paid in cash in tranches over the next 18 months from closing and the final payment of US $450,000 to be paid in common shares or cash at LED's option 24 months from closing. Concurrent with the acquisition, LED closed a series of financings (see below in "Financings" for details) a portion of which was used to fund the acquisition of Apteryx.


Date: February 13, 2017

Type: Brokered and non-brokered private placements

Issuer: LED Medical Diagnostics Inc.

Agent(s): Bloom Burton Securities Inc.

Deal size: Gross proceeds of approximately US $14.4 million

Description: Concurrent with LED's acquisition of Apteryx (see above in "Mergers & Acquisitions" for details), LED announced on February 13, 2017 that it had completed a series of brokered and non-brokered private placements of both equity and debenture units as follows:

  • a brokered private placement of equity units of LED (each an "Equity Unit"), at a price of $0.06 per Equity Unit for gross proceeds of approximately CDN $11.5 million, with each Equity Unit consisting of one common share and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"), with each Warrant exercisable for a period of 24 months into one common share of LED at a price of $0.10 per common share;
  • a brokered private placement of 88 debenture units of LED (the "Debenture Units") for gross proceeds of CDN $880,000, with each Debenture Unit consisting of CDN $10,000 principal value 12% senior secured debentures maturing 24 months from the closing date and 21,250 common shares of LED;
  • a non brokered private placement of Equity Units for gross proceeds of approximately CDN $1.8 million;
  • a non-brokered private placement of 27 Debenture Units for gross proceeds of CDN $270,000.

A portion of the net proceeds was used to fund the acquisition of Apteryx. LED, through its wholly owned subsidiaries, provides dentists and oral health specialists with diagnostic imaging products and software.

Date: February 15, 2017

Type: Short-form prospectus offering

Issuer: CannaRoyalty Corp. ("CannaRoyalty") (CSE: CRZ)

Underwriter(s): A syndicate of underwriters led by Canaccord Genuity Corp.

Deal size: Aggregate gross proceeds of CDN $15 million

Description: On February 15, 2017, CannaRoyalty announced the closing of a short-form prospectus offering (the "Offering") for aggregate gross proceeds of CDN $15,000,000. The Offering was for an aggregate of 5,000,000 units (the "Units") at a price of $3.00 per Unit. Each Unit comprises one common share of CannaRoyalty (a "Common Share") and half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant"). Each Warrant is exercisable to acquire one Common Share (a “Warrant Share”) for a period of 2 years at an exercise price of $4.50 per Warrant Share. The Warrants will be subject to a 21-day forced exercise provision if CannaRoyalty’s daily volume weighted average share price is greater than $6.00 for 15 consecutive trading days following closing. The Offering was completed by a syndicate of underwriters led by Canaccord Genuity Corp.

Date: Announced as closed on February 23, 2017

Type: Series A financing

Issuer: Fusion Pharmaceuticals Inc. ("Fusion")

Investor(s): Johnson & Johnson Innovation, HealthCap, TPG Biotech, Genesys Capital, Fight Against Cancer Innovation Trust

Deal size: US $25 million (approx. CDN $32.78 million)

Description: On February 23, 2017, Hamilton-based Fusion announced the closing of a US $25 million Series A financing led by Johnson & Johnson Innovation, and with investments by HealthCap, TPG Biotech, Genesys Capital and Fight Against Cancer Innovation Trust. Fusion will use the proceeds to advance its lead program, an antibody-targeted radiotherapy for treatment of refractory cancers, into human clinical trials.

Date: February 23, 2017

Type: Non-brokered private placement

Issuer: ProMIS Neurosciences Inc. ("ProMIS") (TSX: PMN)

Deal size: CDN $2,719,813

Description: On February 23, 2017, ProMIS announced the closing of its non-brokered private placement, originally announced on February 6, 2017, for total gross proceeds of CDN $2,719,813. ProMIS issued a total of 18,757,331 units (“Units”) at $0.145 per Unit in two closings raising gross proceeds of CDN$2,719,813, with 15,848,863 Units being issued in the first closing (as announced on Feb. 13, 2017) and the balance in the second closing.  Each Unit consisted of one common share of the Company and one-half of a common share purchase warrant, with each whole warrant being exercisable into one common share at a price of $0.20 per share for 36 months from the issue date. ProMIS develops therapeutics for neurodegenerative diseases such as Alzheimer's Disease and ALS.

Date: February 24, 2017

Type: Brokered and non-brokered private placements

Issuer: RepliCel Life Sciences Inc. ("RepliCel") (TSX.V: RP)

Agent(s): Echelon Wealth Partners Inc. (“Echelon”), Haywood Securities Inc. and Clarus Securities Inc. (collectively, the "Agents")

Deal size: Total gross proceeds of CDN $3,165,125

Description: On February 24, 2017, RepliCel completed a financing for total gross proceeds of CDN $3,165,125. The financing consisted of a brokered private placement of 2,181,300 units (each a “Unit”) at a price of $1.25 per Unit (the “Brokered Financing”) and a non-brokered private placement of 350,800 Units at a price of $1.25 per Unit (the “Non-Brokered Financing” and, together with the Brokered Financing, the “Financing”). Each Unit consisted of one common share of the Company (each, a “Share”) and one share purchase warrant (each, a “Warrant”), with each Warrant entitling the holder to purchase one additional Share for a period of three years from the closing of the Financing at a price of $2.00 per Share. RepliCel is a regenerative medicine company focusing on developing autologous cell therapies for certain conditions.

Date: February 28, 2017

Type: Bought deal private placement

Issuer: Aurora Cannabis Inc. ("Aurora") (TSX.V: ACB)

Underwriter(s): A syndicate of investment dealers led by Canaccord Genuity Corp. and including Cormark Securities Inc., Eight Capital, Mackie Research Capital Corporation and GMP Securities L.P. (collectively, the "Underwriters")

Deal size: Gross proceeds of $75 million

Description: On February 28, 2017, Aurora announced the completion of a bought deal private placement, pursuant to which Aurora issued 33,333,357 units ("Units") at a price of $2.25 per Unit for gross proceeds of $75 million. Each Unit was comprised of one common share of Aurora (a "Common Share") and half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant is exercisable to acquire one Common Share of Aurora (a "Warrant Share") for a period of 2 years at an exercise price of $3.00 per Warrant Share, subject to adjustments and acceleration under certain circumstances.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.